Advantage

Main information

  • Trade name:
  • Advantage 80 mg Feline and Bunny Spot-on Solution
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Advantage 80 mg Feline and Bunny Spot-on Solution
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • imidacloprid
  • Therapeutic area:
  • Cats, Rabbit

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0389/002
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0389/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:01261/2010

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Advantage80mgfelineandbunnySpot-onsolution[UK]

Advantage80mgSpot-onsolutionforLargeCatsandLargePetRabbits[AT,DE,FR,

IE,IT]

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each0.8mlpipettecontains:

Activesubstance:

Imidacloprid 80mg

Excipient(s):

Butylhydroxytoluene(E321) 0.8mg

Benzylalcohol 665.6mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution

Clearyellowtoslightlybrownishsolution

4. CLINICALPARTICULARS

4.1Targetspecies

Catsandpetrabbits

4.2Indicationsforuse,specifyingthetargetspecies

Forcatsof4kgandgreater:

Preventionandtreatmentoffleainfestations.

.

Forpetrabbitsof4kgandgreater:

Treatmentoffleainfestations.

Fleasarekilledwithinonedayfollowingtreatment.Onetreatmentpreventsfurtherflea

infestationforthreetofourweeksoncatsanduptooneweekonpetrabbits.The

productcanbeusedaspartofatreatmentstrategyforthecontrolofFleaAllergy

Issued:December2011

AN:01261/2010

Page2of7

Dermatitis(FAD)incats,wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

4.3Contraindications

Donottreatunweanedkittensoflessthan8weeksofage.

Donotuseonrabbitsintendedforhumanconsumption.

Donotuseonpetrabbitsoflessthan10weeksofage.

Donotuseinanimalsthatareknowntobehypersensitivetotheactivesubstanceorany

oftheexcipients.

4.4Specialwarnings

Re-infestationfromemergenceofnewfleasintheenvironmentmaycontinuetooccurfor

sixweeksorlongeraftertreatmentisinitiated.Morethanonetreatmentmaytherefore

berequired,dependingontheleveloffleasintheenvironment.Toaidreductionin

environmentalchallenge,theadditionaluseofasuitableenvironmentaltreatment

againstadultfleasandtheirdevelopingstagesisrecommended.Inordertoreduce

furthertheenvironmentalchallenge,itisrecommendedthatalldogs,catsandrabbitsin

thehouseholdaretreated.Treatmentofnursingqueensanddoescontrolsflea

infestationsonbothdamandoffspring.

Theproductremainseffectiveiftheanimalbecomeswet,forexampleafterexposureto

heavyrain.However,re-treatmentmaybecomenecessary,dependingonthepresence

offleasintheenvironment.Inthesecasesdonottreatmorefrequentlythanonceweekly.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thisproductisfortopicaluseandshouldnotbeadministeredorally.

Applyonlytoundamagedskin

Careshouldbetakentoavoidthecontentsofthepipettecomingintocontactwiththe

eyesormouthoftherecipientanimal.

Donotallowrecentlytreatedanimalstogroomeachother.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsthoroughlyafteruse.

Washoffanyskincontaminationwithsoapandwater.

Peoplewithknownskinsensitivitymaybeparticularlysensitivetothisproduct.

Avoidcontactoftheproductwiththeeyesormouth.

Iftheproductgetsintoeyesaccidentally,theeyesshouldbethoroughlyflushedwith

water.Ifskinoreyeirritationpersists,ortheproductisaccidentallyswallowed,obtain

medicalattention.

Donoteat,drinkorsmokeduringapplication.

Issued:December2011

AN:01261/2010

Page3of7

4.6Adversereactions(frequencyandseriousness)

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationanddisap-

pearswithinsomeminuteswithouttreatment(seealsosection4.9Amountstobe

administeredandadministrationroute).

Inveryrareoccasionsskinreactionssuchashairloss,redness,itchingandskinlesions

mayoccurincatsandrabbits.Agitation, excessivesalivationandnervoussignssuchas

incoordination,tremorsanddepressionhavealsobeenreportedbutexceptionallyin

cats.

4.7Useduringpregnancy,lactationorlay

Sincenoprimaryembryotoxic,teratogenicorreproductivetoxiceffectshavebeen

observedduringthestudieswithimidaclopridonratsandrabbitstheproductcanbe

usedinpregnantorlactatingdoes.Studiesonpregnantandlactatingqueenstogether

withtheiroffspringarelimited.Evidencesofarsuggeststhatnoadverseeffectsareto

beexpectedintheseanimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noincompatibilityhasbeenobservedbetweenthisproductattwicetherecommended

doseandthefollowingcommonlyusedveterinaryproducts:lufenuron,pyranteland

praziquantel(cats).Thecompatibilityoftheproductwasalsodemonstratedwithawide

rangeofroutinetreatmentsunderfieldconditionsincludingvaccination.

4.9Amountstobeadministeredandadministrationroute

DosageandTreatmentSchedule

Cat/Rabbit(kgbw) Product Numberof

Pipettes Imidacloprid

(mg/kgbw)

≥4kg Advantage ® 80forLarge

CatsandLargePet

Rabbits 1x0.8ml minimumof10

MethodofAdministration

Removeonepipettefromthepackage.Holdpipetteinanuprightposition,twistandpull

offcap.Usereversedcaptotwistandremovesealfrompipette.

Issued:December2011

AN:01261/2010

Page4of7

AdministrationtotheCat

Partthehaironthecat'sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthepipetteontheskinandsqueezefirmlyseveraltimestoemptythecontents

directlyontotheskin.

AdministrationtotheRabbit

Partthehairontherabbit’sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthetubeontheskinandsqueezefirmlyseveraltimestoemptythecontentsdirectly

ontotheskin.

AllSpecies

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationand

disappearswithinsomeminuteswithouttreatment.Applicationatthebaseoftheskull

willminimizetheopportunityforthecattolicktheproduct.

Applyonlytoundamagedskin.Donotallowrecentlytreatedanimalstogroomeach

other.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incats,noadverseclinicalsignswereproducedusingdosesoffivetimesthe

therapeuticlevelweeklyforeightconsecutiveweeks.

Inrabbits,noadverseclinicalsignswereseenusingdosesofupto45mg/kgbody

weight(4timesthetherapeuticlevel)weeklyfor4consecutiveweeks.

Inrarecasesofoverdoseorlickingoftreatedfur,nervoussystemdisorders(suchas

twitching,tremors,ataxia,mydriasis,miosis,lethargy)canoccurincats.

Issued:December2011

AN:01261/2010

Page5of7

Poisoningfollowinginadvertentoraluptakeinanimalsisunlikely.Inthisevent,treatment

shouldbesymptomaticunderveterinarymedicalattention.Thereisnoknownspecific

antidotebutadministrationofactivatedcharcoalmaybebeneficial.

4.11Withdrawalperiod(s)

Donotuseonrabbitsintendedforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:antiparasiticagent

ATCvetcode:QP53AX17

5.1Pharmacodynamicproperties

Imidacloprid,1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamineisan

ectoparasiticidebelongingtoagroupofchloronicotinylcompounds.Chemically,itis

moreaccuratelydescribedasachloronicotinylnitroguanidine.

Thesubstancehasahighaffinityforthenicotinergicacetylcholinereceptorsinthepost-

synapticregionofthecentralnervoussystem(CNS).Theensuinginhibitionof

cholinergictransmissionininsectsresultsinparalysisanddeath.Duetotheweak

natureoftheinteractionwithmammaliannicotinergicreceptorsitesandthepostulated

poorpenetrationthroughtheblood/brainbarrierinmammals,ithasvirtuallynoeffecton

themammalianCNS.Theminimalpharmacologicalactivityinmammalsissupportedby

safetystudiesinvolvingsystemicadministrationofsub-lethaldosestorabbits,miceand

rats.

Infurtherstudies,inadditiontotheadulticidefleaefficacyofimidacloprid,alarvicidal

fleaefficacyinthesurroundingsofthetreatedpethasbeendemonstrated.Larval

stagesinthepet’ssurroundingsarekilledfollowingcontactwithatreatedanimal.

5.2Pharmacokineticparticulars

Theproductisindicatedforcutaneousadministration.Followingtopicalapplicationin

cats,thesolutionisquicklydistributedovertheanimal.Acutedermalstudiesintherat

andtargetanimaloverdoseandserumkineticstudieshaveestablishedthatsystemic

absorptionisverylow,transientandnotrelevantfortheclinicalefficacy.Thishasbeen

furtherdemonstratedbyastudyinwhichfleaswerenotkilledafterhavingfedon

previouslytreatedanima lsoncetheanimal’sskinandfurhadbeencleanedofallactive

material.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Issued:December2011

AN:01261/2010

Page6of7

ButylhydroxytolueneE321

Benzylalcohol

Propylenecarbonate

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:

5years

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Keeptheblisterintheoutercarton

6.5Natureandcompositionofimmediatepackaging

Packsizes 0.8mlsolutionperpipette

Blisterpackcontaining2,3,4,or6unitdosepipettes

Container Whitepolypropylenepipetteswithcaps

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

Bayerplc

AnimalHealthDivision

BayerHouse

StrawberryHill

Newbury

Berkshire

RG141JA

8. MARKETINGAUTHORISATIONNUMBER

Issued:December2011

AN:01261/2010

Page7of7

Vm00010/4178

9. DATEOFFIRSTAUTHORISATION

7December2011

10.DATEOFREVISIONOFTHETEXT

December2011

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

28-11-2018

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

Health Canada

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

17-10-2018

Pest categorisation of Stagonosporopsis andigena

Pest categorisation of Stagonosporopsis andigena

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The Panel on Plant Health performed a pest categorisation of Stagonosporopsis andigena, the causal agent of black blight of potato, for the EU. The pest is a well‐defined fungal species and reliable methods exist for its detection and identification. S. andigena is present in Bolivia and Peru. The pest is not known to occur in the EU and is listed in Annex IAI of Directive 2000/29/EC as Phoma andina, meaning its introduction into the EU is prohibited. The ma...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

20-8-2018

Danish Medicines Agency lands new European chairmanship

Danish Medicines Agency lands new European chairmanship

Nikolai Brun, Director of Medical Evaluation & Biostatistics, has been elected chair of the Task Force on Big Data in the pharmaceutical area. The task force is a collaboration between the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) which is to identify advantages and challenges of using big data for the development of medicine.

Danish Medicines Agency

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

12-7-2018

Minister Bruno Bruins bereikt akkoord over vergoeding Spinraza

Minister Bruno Bruins bereikt akkoord over vergoeding Spinraza

Minister Bruno Bruins (Medische Zorg) heeft  een akkoord bereikt met fabrikant Biogen. Hierdoor komt het middel Spinraza voor circa 80 jonge kinderen met de spierziekte Spinale Musculaire Atrofie (SMA) vanaf 1 augustus in het basispakket.  

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

3-5-2018

FDA Approves Application for AquaBounty Salmon Facility in Indiana

FDA Approves Application for AquaBounty Salmon Facility in Indiana

FDA approved a supplemental New Animal Drug Application submitted by AquaBounty Technologies, Inc. The supplemental NADA requested FDA approval to raise AquAdvantage Salmon at a land-based contained facility near Albany, Indiana.

FDA - U.S. Food and Drug Administration

6-4-2018

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

Health Canada is advising Canadians that one lot of “Organic Traditions Shatavari Powder” is being voluntarily recalled by Advantage Health Matters Inc. Company testing found Salmonella bacteria contamination, which may pose serious health risks. According to Advantage Health Matters Inc., 13 units from the affected lot were distributed. Of the 13 units, only 2 packages, sold at Choices Markets Yaletown (1202 Richards Street) in Vancouver, B.C., have not been recovered.

Health Canada

1-8-2018

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Active substance: Meningococcal group A, C, W-135 and Y conjugate vaccine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5220 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2226/T/80

Europe -DG Health and Food Safety

28-5-2018

Seresto and its associated name Foresto

Seresto and its associated name Foresto

Seresto and its associated name Foresto (Active substance: imidacloprid/flumethrin) - Community Referrals - Art 13 - Commission Decision (2018)3404 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/125

Europe -DG Health and Food Safety